Drug Trial Radar · NCT05938699
Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution
Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Dec 12, 2023
Primary completion
Mar 17, 2025
Study completion Mar 17, 2025
Sponsor
- Lead sponsor
- Nicox Ophthalmics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a double-masked, placebo-controlled study which will determine the action of NCX 470 ophthalmic solution, 0.1% on aqueous humor dynamic parameters in healthy volunteers or subjects with OHT.
Conditions
- Open Angle Glaucoma
Interventions
NCX 470Drug
NCX 470 0.1% vs Placebo
PlaceboDrug
NCX 0.1% vs Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in AHDTime frame: 8 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.